Galderma Group AG (GALDY)
The price, the headline numbers and the latest news, in one place.
Galderma Group AG (GALDY) Stock Price, Analysis & Data
| Bid | 38.23 |
| Market Cap | 44.6B |
| Revenue (ttm) | 5.92B |
| Net Income (ttm) | 863M |
| -0.11 | |
| 0.7 | |
| 54.67 | |
| 6.05 | |
| P/B (ttm) | 5.43 |
| P/S (ttm) | 7.53 |
| Earnings Date | n/a |
| Ask | 38.27 |
| Volume | 22,214 |
| Avg. Volume (20D) | 133,814 |
| Open | 39.50 |
| Previous Close | 39.03 |
| Day's Range | 38.19 - 39.50 |
| 52-Week Range | 33.13 - 46.31 |
| Analyst | n/a |
| Price Target | 50.98 (33.21%) |
| Dividends | $0.09 (0.23%) |
| Ex-Dividend Date | Apr 27, 2026 |
About GALDY
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix...
Financial Performance
In 2025, Galderma's revenue was 5.24B, an increase of 18.04% compared to the previous year's 4.44B. Earnings were 613M, an increase of 165.37%.
Financial StatementsAnalyst Forecast
According to 1 analyst ratings, the average rating for GALDY stock is "null". The 12-month stock price forecast is 50.98, which is upside of 33.21% from the latest price.
Stock ForecastsEarnings Surprise
- Revenue of n/a misses estimates by $0, with NaN% YoY growth.
- EPS of misses estimates by , with NaN% YoY growth.
